American Association for Cancer Research

SHERPA: Unknown

People

  1. Solit
    Solit
  2. Ladanyi
    Ladanyi
  3. Rosen
    Rosen
  4. Hudis
    Hudis
  5. Scher
    Scher
  6. Baselga
    Baselga
  7. Berger
    Berger
  8. Norton
    Norton
  9. Reis-Filho
    Reis-Filho
  10. Cordon-Cardo
    Cordon-Cardo

Groups

  1. Department of Medicine (2138)
  2. Solid Tumor Oncology Division (1789)
  3. GSK Faculty (1641)
  4. Sloan Kettering Institute Faculty (788)
  5. Sloan Kettering Institute Postdocs (787)
  6. Department of Pathology and Laboratory Medicine (744)
  7. Human Oncology and Pathogenesis Program (687)
  8. Surgery (647)
  9. Breast Medicine Service (611)
  10. Center for Molecular Imaging and Biotechnology (CMIB) (589)
Search Within
Formats
  1. Journal Article (2035)
  2. Meeting Abstract (2011)
  3. Editorial (49)
  4. Review (29)
  5. Conference Paper (14)
  6. Correspondence (6)
  7. Miscellaneous (4)
  8. Guidelines (1)
Groups
  1. Department of Medicine (2138)
  2. Solid Tumor Oncology Division (1789)
  3. GSK Faculty (1641)
  4. Sloan Kettering Institute Faculty (788)
  5. Sloan Kettering Institute Postdocs (787)
  6. Department of Pathology and Laboratory Medicine (744)

More Groups

People
  1. David Solit (176)
  2. Marc Ladanyi (158)
  3. Neal Rosen (142)
  4. Clifford Hudis (141)
  5. Howard Scher (139)
  6. Jose Baselga (138)

More People

Years
  1. 2025 (51)
  2. 2024 (75)
  3. 2023 (79)
  4. 2022 (266)
  5. 2021 (235)
  6. 2020 (272)

More Years

Publications
  1. Cancer Research (2704)
  2. Clinical Cancer Research (1445)

Results (4149)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Unraveling Ewing sarcoma tumorigenesis originating from patient-derived mesenchymal stem cells
    Journal Article

    Sole, A.; Grossetête, S.; Heintzé, M.; Babin, L.; Zaïdi, S.; Revy, P.; Renouf, B.; De Cian, A.; Giovannangeli, C.; Pierre-Eugène, C.; more...
    Cancer Research (2021)

    Fulltext@MSK | Save
  • TET2 and DNMT3A mutations exert divergent effects on DNA repair and sensitivity of leukemia cells to PARP inhibitors
    Journal Article

    Maifrede, S.; Le, B. V.; Nieborowska-Skorska, M.; Golovine, K.; Sullivan-Reed, K.; Dunuwille, W. M. B.; Nacson, J.; Hulse, M.; Keith, K.; Madzo, J.; more...
    Cancer Research (2021)

    Fulltext@MSK | Save
  • Activation of the IFN signaling pathway is associated with resistance to CDK4/6 inhibitors and immune checkpoint activation in ER-positive breast cancer
    Journal Article

    De Angelis, C.; Fu, X. Y.; Cataldo, M. L.; Nardone, A.; Pereira, R.; Veeraraghavan, J.; Nanda, S.; Qin, L. F.; Sethunath, V.; Wang, T.; more...
    Clinical Cancer Research (2021)

    Fulltext@MSK | Save
  • BET bromodomain inhibition blocks an AR-repressed, E2F1-activated treatment-emergent neuroendocrine prostate cancer lineage plasticity program
    Journal Article

    Kim, D. H.; Sun, D.; Storck, W. K.; Leng, K. W.; Jenkins, C.; Coleman, D. J.; Sampson, D.; Guan, X.; Kumaraswamy, A.; Rodansky, E. S.; more...
    Clinical Cancer Research (2021)

    Fulltext@MSK | Save
  • Immunotherapy-mediated thyroid dysfunction: Genetic risk and impact on outcomes with PD-1 blockade in non-small cell lung cancer
    Journal Article

    Luo, J.; Martucci, V. L.; Quandt, Z.; Groha, S.; Murray, M. H.; Lovly, C. M.; Rizvi, H.; Egger, J. V.; Plodkowski, A. J.; Abu-Akeel, M.; more...
    Clinical Cancer Research (2021)

    Fulltext@MSK | Save
  • RASAL2 confers collateral MEK/EGFR dependency in chemoresistant triple-negative breast cancer
    Journal Article

    Koh, S. B.; Ross, K.; Isakoff, S. J.; Melkonjan, N.; He, L.; Matissek, K. J.; Schultz, A.; Mayer, E. L.; Traina, T. A.; Carey, L. A.; more...
    Clinical Cancer Research (2021)

    Fulltext@MSK | Save
  • NECTIN4 heterogeneity and molecular diversity in bladder cancers: Deconstructing the activity of an antibody-drug conjugate
    Editorial

    Teo, M. Y.; Rosenberg, J. E.
    Clinical Cancer Research (2021)

    Fulltext@MSK | Save
  • A phase I dose-escalation and expansion study of telaglenastat in patients with advanced or metastatic solid tumors
    Journal Article

    Harding, J. J.; Telli, M.; Munster, P.; Voss, M. H.; Infante, J. R.; DeMichele, A.; Dunphy, M.; Le, M. H.; Molineaux, C.; Orford, K.; more...
    Clinical Cancer Research (2021)

    Fulltext@MSK | Save
  • Vorasidenib, a dual inhibitor of mutant IDH1/2, in recurrent or progressive glioma; Results of a first-in-human phase I trial
    Journal Article

    Mellinghoff, I. K.; Penas-Prado, M.; Peters, K. B.; Burris, H. A. 3rd; Maher, E. A.; Janku, F.; Cote, G. M.; de la Fuente, M. I.; Clarke, J. L.; Ellingson, B. M.; more...
    Clinical Cancer Research (2021)

    Fulltext@MSK | Save
  • A phase Ib study of atezolizumab with radium-223 dichloride in men with metastatic castration-resistant prostate cancer
    Journal Article

    Fong, L.; Morris, M. J.; Sartor, O.; Higano, C. S.; Pagliaro, L.; Alva, A.; Appleman, L. J.; Tan, W.; Vaishampayan, U.; Porcu, R.; more...
    Clinical Cancer Research (2021)

    Fulltext@MSK | Save

    • American Association for Cancer Research – authorized name for: